Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects

(2020) Julie Crockett et al.   EPILEPSIA

A cautious hope for cannabidiol (CBD) in rheumatology care

(2020) Mary‐Ann Fitzcharles et al.   ARTHRITIS CARE & RESEARCH

From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases

(2020) Tommaso Cassano et al.   Frontiers in Pharmacology

A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment

(2019) Lesley Taylor et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy

(2019) Valentina Franco et al.   DRUGS

Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy

(2019) Angela K. Birnbaum et al.   EPILEPSIA

Cannabidiol—from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer

(2019) Brigitta Kis et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment

(2019) Bola Tayo et al.   CLINICAL PHARMACOKINETICS

Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system

(2018) Jong Bong Lee et al.   JOURNAL OF CONTROLLED RELEASE

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

(2018) Lesley Taylor et al.   CNS DRUGS

Lymphatic Drug Absorption via the Enterocytes: Pharmacokinetic Simulation, Modeling, and Considerations for Optimal Drug Development

(2018) Dion R. Brocks et al.   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans

(2018) Sophie A. Millar et al.   Frontiers in Pharmacology

Pharmacology of cannabinoids in the treatment of epilepsy

(2017) Tyler E. Gaston et al.   EPILEPSY & BEHAVIOR

Cannabidiol: State of the art and new challenges for therapeutic applications

(2017) Simona Pisanti et al.   PHARMACOLOGY & THERAPEUTICS

Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage

(2016) Rosa Chan et al.   AAPS Journal

Treatment of Dravet Syndrome

(2016) Elaine C. Wirrell   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Cannabinoids and Cytochrome P450 Interactions

(2016) Ondřej Zendulka et al.   CURRENT DRUG METABOLISM

Cannabidiol, neuroprotection and neuropsychiatric disorders

(2016) Alline C. Campos et al.   PHARMACOLOGICAL RESEARCH

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy

(2015) Alexandra L. Geffrey et al.   EPILEPSIA

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

(2013) Colin Stott et al.   SpringerPlus

Novel Δ9-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects

(2012) Linda E. Klumpers et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Oromucosal Midazolam

(2012) Karly P. Garnock-Jones   PEDIATRIC DRUGS

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes

(2011) Rongrong Jiang et al.   LIFE SCIENCES

Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology

(2008) Alexis Arzimanoglou et al.   LANCET NEUROLOGY